Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Axiban
- Development stage
- Unknown
- Lead developer
- Panaxia Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Sublingual, Topical
01
Overview
Axiban is a brand of medical cannabis products developed through a partnership between Panaxia Pharmaceutical Industries, Rafa Laboratories, and PlantEXT. Primarily marketed in Israel by Rafa Laboratories, Axiban is widely known as a line of sublingual drops containing precise, standardized ratios of tetrahydrocannabinol (THC) and cannabidiol (CBD). These sublingual formulations are prescribed for various indications approved by the Israeli Ministry of Health, including chronic neuropathic pain, metastatic cancer pain, chemotherapy-induced nausea and vomiting (CINV), and spasticity in multiple sclerosis. Additionally, under the same brand name, PlantEXT has developed a topical CBD and terpene-rich cream formulation specifically targeted at relieving arthritis and joint pain.
- Brand names
- Axiban
- Other names
- Axiban OilAxiban Sublingual DropsAxibaneAxivan
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Axiban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axiban.